para]]New research suggests CD39 capable of clearing plaque that leads to heart attacks, strokes[[/para]]
In a new study published online ahead of print in the August issue of the Journal of Clinical Investigation, scientists at the University of Michigan Health System used mice to show that a human membrane-bound enzyme called CD39, which can clear the dangerous buildup of adenosine triphosphate (ATP) from the bloodstream, significantly reduces atherosclerosis in mice.
CD38 belongs to an increasingly recognised large number of lymphocyte ecto-enzymes (CD157, CD39
and CD73), which are involved in adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NAD) metabolism.
Brigham and Women's Hospital, Harvard Medical School CD39
modulates NKT cell-induced oxygen toxicity in the lung
The detection of the CD39 mutation required the most stringent conditions to differentiate between normal and heterozygous samples, so the conditions selected for this mutation were subsequently applied to the differentiation of normal, mutant, and heterozygous samples for all the other mutations.
A normal sample and a CD39 heterozygous sample were analyzed in parallel, N/M was determined at each enzyme activity, and then the ratio N/M (normal)/N/M (heterozygous) was calculated and plotted vs the enzyme activity.
This study was undertaken to examine the tissue distribution of a broad spectrum of monoclonal antibodies (mAbs) containing tetraspan antigens (CD9, CD63, CD151), endothelial cell antigens (CD31, CD36, CD105, CD106, CD146), integrins (CD49a-f, CD29, CD41, CD51, CD61), CD39, CD98, CD99, CD143 and, CD147 supplied from fifth and sixth international workshops and conferences on human leukocyte differentiation antigens in a comparative manner in human OA and normal synovium.
CD39, CD99, CD143, and CD147 presented a restricted expression pattern basically limited to the vascular endothelium with no statistically significant difference among groups (Table 3).
Rathmann has been instrumental in helping us as we continue to shift out of our gene discovery stage and into development of product candidates such as our IL-1Hy and CD39
product candidates," Mr.
Hyseq and the Imperial Cancer Research Fund have now reported four CD39
The results of collaborative studies that uncovered the biological role of CD39
were published in the current issue of the Journal of Clinical Investigation by Aaron J.
Preclinical work began on a new molecule, CD39
, which is of interest as an anti-thrombotic due to the role it plays in platelet aggregation.